IL6 and lung disorder: Our study delineates T cells as a reliable biomarker for evaluating VOCs‐induced lung diseases, provides a novel insight into immunological mechanisms from in situ lung and distal BM hematopoiesis, and offers potential targets (i.e., IL‐6 and IL‐17A) for therapeutic intervention of VOCs‐associated obstructive lung diseases.